The Lynx Group

The Mechanism of Action of CDK4/6 Inhibitors

Videos — January 10, 2018

Featuring:

Dr Matthew Goetz explains the rationale for using CDK4/6 inhibitors in patients with HR-positive metastatic breast cancer.

Related Articles

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to recieve the free VBCC print publication or weekly e‑Newsletter.

I'd like to recieve: